![Beate Stern](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Beate Stern
Fondatore presso Uni Targeting Research AS
Profilo
Beate Stern is the founder of Uni Targeting Research AS, which was founded in 2001.
She held the title of Chief Scientific Officer at the company.
Currently, Dr. Stern is working as an Associate Professor at the University of Bergen.
In the past, she worked as a Principal at the Max-Planck-Institute for Molecular Genetics.
Posizioni attive di Beate Stern
Società | Posizione | Inizio |
---|---|---|
Uni Targeting Research AS
![]() Uni Targeting Research AS BiotechnologyHealth Technology Uni Targeting Research AS is a holding company that provides the biopharmaceutical industry with tools and services for mammalian cell-line based development procedures and production processes. It offers upstream solutions to reduce complementary deoxyribonucleic acid and mammalian cell-line based timelines and increase protein production yields. Its technology enables both enhanced synthesis/secretion of naturally secreted proteins, and secretion of intracellular proteins. Its services include vector improvement, tailor-made vectors, and tool proteins. The company was founded by Ian Fraser Pryme, John E. Hesketh, Albert Tauler, and Beate Stern in 2001 and is headquartered in Bergen, Norway. | Fondatore | 28/07/2009 |
University of Bergen | Corporate Officer/Principal | - |
Precedenti posizioni note di Beate Stern
Società | Posizione | Fine |
---|---|---|
Max-Planck-Institute for Molecular Genetics | Corporate Officer/Principal | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 1 |
---|---|
Uni Targeting Research AS
![]() Uni Targeting Research AS BiotechnologyHealth Technology Uni Targeting Research AS is a holding company that provides the biopharmaceutical industry with tools and services for mammalian cell-line based development procedures and production processes. It offers upstream solutions to reduce complementary deoxyribonucleic acid and mammalian cell-line based timelines and increase protein production yields. Its technology enables both enhanced synthesis/secretion of naturally secreted proteins, and secretion of intracellular proteins. Its services include vector improvement, tailor-made vectors, and tool proteins. The company was founded by Ian Fraser Pryme, John E. Hesketh, Albert Tauler, and Beate Stern in 2001 and is headquartered in Bergen, Norway. | Health Technology |
- Borsa valori
- Insiders
- Beate Stern